Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

2.

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

Dagan R.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. doi: 10.1111/j.1469-0691.2009.02726.x. Review.

4.

Pneumococcal serotype evolution in Western Europe.

Tin Tin Htar M, Christopoulou D, Schmitt HJ.

BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. Review.

5.

Continued control of pneumococcal disease in the UK - the impact of vaccination.

Gladstone RA, Jefferies JM, Faust SN, Clarke SC.

J Med Microbiol. 2011 Jan;60(Pt 1):1-8. doi: 10.1099/jmm.0.020016-0. Epub 2010 Oct 21. Review.

PMID:
20965923
6.

13-valent pneumococcal conjugate vaccine (PCV13).

Jefferies JM, Macdonald E, Faust SN, Clarke SC.

Hum Vaccin. 2011 Oct;7(10):1012-8. doi: 10.4161/hv.7.10.16794. Epub 2011 Oct 1. Review.

PMID:
21941097
7.

Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines.

Falup-Pecurariu O.

Biomed J. 2012 Nov-Dec;35(6):450-6. doi: 10.4103/2319-4170.104409. Review.

8.

Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Tan TQ.

Clin Microbiol Rev. 2012 Jul;25(3):409-19. doi: 10.1128/CMR.00018-12. Review.

9.

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres A, Bonanni P, Hryniewicz W, Moutschen M, Reinert RR, Welte T.

Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):19-31. doi: 10.1007/s10096-014-2208-6. Epub 2014 Aug 23. Review. Erratum in: Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):415-6.

10.

Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.

Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.

Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9. doi: 10.1111/1469-0691.12320. Review.

11.

Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger.

McEllistrem MC, Nahm MH.

Clin Infect Dis. 2012 Nov 15;55(10):1379-86. doi: 10.1093/cid/cis691. Epub 2012 Aug 16. Review.

12.

Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010.

Castañeda E, Agudelo CI, De Antonio R, Rosselli D, Calderón C, Ortega-Barria E, Colindres RE.

BMC Infect Dis. 2012 May 28;12:124. doi: 10.1186/1471-2334-12-124. Review.

13.

A conjugate vaccine for the prevention of pediatric pneumococcal disease.

Murray D, Jackson C.

Mil Med. 2002 Aug;167(8):671-7. Review.

PMID:
12188240
14.

Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines.

Ansaldi F, de Florentis D, Canepa P, Bandettini R, Diana MC, Martini M, Durando P, Icardi G.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:211-6. doi: 10.4161/hv.7.0.14602. Review.

PMID:
21546795
15.

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

Hausdorff WP, Hoet B, Schuerman L.

BMC Pediatr. 2010 Feb 2;10:4. doi: 10.1186/1471-2431-10-4. Review.

16.

Global prevailing and emerging pediatric pneumococcal serotypes.

McIntosh ED, Reinert RR.

Expert Rev Vaccines. 2011 Jan;10(1):109-29. doi: 10.1586/erv.10.145. Review.

PMID:
21162625
17.

Streptococcus pneumoniae serotype distribution in children in the Russian Federation before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.

Tatochenko V, Sidorenko S, Namazova-Baranova L, Mayanskiy N, Kulichenko T, Baranov A, Lobzin Y, Kharit S, Kozlov R, Andreeva I, Muravjev A, Chagaryan A, Koroleva I, Beloshitskiy G, Mironov K, Degtyareva E, Reinert RR.

Expert Rev Vaccines. 2014 Feb;13(2):257-64. doi: 10.1586/14760584.2013.871205. Epub 2013 Dec 18. Review.

PMID:
24350587
18.

Ten years of experience with the pneumococcal conjugate 7-valent vaccine in children.

Weil Olivier C.

Med Mal Infect. 2013 Aug;43(8):309-21. doi: 10.1016/j.medmal.2013.04.006. Epub 2013 Jul 8. Review.

PMID:
23845250
19.

Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?

Weil-Olivier C, Gaillat J.

Vaccine. 2014 Apr 11;32(18):2022-6. doi: 10.1016/j.vaccine.2014.02.008. Epub 2014 Feb 22. Review.

PMID:
24565755
20.

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.

Esposito S, Principi N.

J Immunol Res. 2015;2015:591580. doi: 10.1155/2015/591580. Epub 2015 Aug 17. Review.

Items per page

Supplemental Content

Write to the Help Desk